Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARM101 for prevention of delayed graft function after kidney transplantation (Phase I/II)
CTR20263336Phase 2Active
- Sponsor
- Guangzhou Huayue Renal Regenerative Medicine Technology
- Start
- Aug 2026
- Modality
- Gene Therapies, RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mi405 in delayed graft function (DGF) and end-stage kidney disease (ESKD), sponsored by Guangzhou Huayue Renal Regenerative Medicine Technology. Primary endpoints: Treatment-related adverse events (type and incidence) and Dose-limiting toxicities (DLT). Started Aug 2026; status: active.
02
Drugs
mi405
03
Conditions
delayed graft function (DGF)end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on CTR20263336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263336.